When switching from a daily GLP-1 receptor agonist, treatment can usually begin the day after the last dose of the daily medication
The Effect Nobody Talks About Cleanly This is where MT-II gets interesting in a different way
Dawed AY, Mari A, Brown A et al (2023) Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomized controlled trials
Jeong SM, Xiao C, Finley LWS, Lahusen T, Souza AL, Pierce K, et al
It employs a highly personalized low and slow titration that we call SmartDose, effectively doubling the number of dose steps and checking in more frequently than the standard protocol
Which tests help evaluate toxic overload and depression